CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been awarded two grants totaling approximately $500,000 under the Patient Protection and Affordable Care Act of 2010. The Company received two separate grants of $244,000 each to support ongoing clinical and preclinical development activities related to the following programs:
